A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
BackgroundHER2-positive molecular breast cancer subtypes are characterized by high aggressiveness and malignancy, and their metastasis and mortality rates are among the highest of all types of breast cancer. The use of anti-HER2-targeted agents in neoadjuvant therapy has significantly improved the p...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2024-02-01
|
| Serie: | Frontiers in Oncology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1281643/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|